// App-Quantinova.ai

: An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Researchers

Presenter

  • Jonathan L. Kaufman

Principal Investigators

  • Hang Quach

  • Rachid C. Baz

  • Annette Juul Vangsted

  • Shir-Jing Ho

  • Simon J Harrison

  • Torben Plesner

  • Philippe Moreau

  • Simon D. Gibbs

  • Eva Medvedova

  • Muhammad Jalaluddin

  • Jeremy A. Ross

  • Leanne Lash Fleming

  • Yan Luo

  • Nizar Jacques Bahlis

Medical Centers

  • Department of Hematology, University of Southern Denmark and Vejle Hospital, Vejle, Denmark

  • Department of Haematology, St George Hospital, Sydney, Australia

  • Hematology Department, University Hospital Hôtel-Dieu, Nantes, France

  • Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada

  • Dept. Hematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark

  • Department of Haematology, Monash University Eastern Health Clinical School, Melbourne, Australia

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

  • Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL

  • Knight Cancer Institute, Oregon Health & Science University, Portland, OR

  • Clinical Haematology Service, St. Vincent's Hospital, Melbourne, Australia

Locations

  • Denmark

  • Canada

  • Australia

  • United States

  • France

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Multinational

  • Multicenteric

  • Expansion Study

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved